Effect of endocrine treatment on prostatic blood flow in patients with prostatic adenocarcinoma. 1988

H Toma, and R Nakamura, and S Onitsuka, and N Goya, and H Nakazawa
Department of Urology, Tokyo Women's Medical College, Japan.

Prostatic blood flow in 19 patients with prostatic adenocarcinoma was measured by the hydrogen gas clearance method before and during endocrine treatment. Prostatic volume was reduced to 70 per cent of the pre-treatment volume by 3 months after the beginning of treatment. Prostatic blood flow was remarkably depressed in patients who had never had any treatment of the prostatic carcinoma (22.2 +/- 8.3 ml. per minute per 100 gm.), while prostatic blood flow increased significantly after endocrine treatment (56.3 +/- 21.8 ml. per minute per 100 gm.). It was likely that prostatic blood flow increased as the prostate volume decreased. Final histology of serial prostatic biopsy specimens after endocrine treatment, revealed distinct deterioration of tumor cells and slight stromal hyperplasia compared to the initial pre-treatment biopsy. The stromal-epithelial ratio, which was calculated by computer-assisted image analysis, was markedly increased after endocrine treatment. Our study indicated that endocrine treatment caused a growth-inhibitory effect that was accompanied by increased blood flow in the prostatic carcinoma.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008937 Mitomycins A group of methylazirinopyrroloindolediones obtained from certain Streptomyces strains. They are very toxic antibiotics used as ANTINEOPLASTIC AGENTS in some solid tumors. PORFIROMYCIN and MITOMYCIN are the most useful members of the group.
D011467 Prostate A gland in males that surrounds the neck of the URINARY BLADDER and the URETHRA. It secretes a substance that liquefies coagulated semen. It is situated in the pelvic cavity behind the lower part of the PUBIC SYMPHYSIS, above the deep layer of the triangular ligament, and rests upon the RECTUM. Prostates
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D012039 Regional Blood Flow The flow of BLOOD through or around an organ or region of the body. Blood Flow, Regional,Blood Flows, Regional,Flow, Regional Blood,Flows, Regional Blood,Regional Blood Flows
D002369 Castration Surgical removal or artificial destruction of gonads. Gonadectomy,Castrations,Gonadectomies
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D004054 Diethylstilbestrol A synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as a growth promoter in animals. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen. (Merck, 11th ed) Stilbestrol,Agostilben,Apstil,Diethylstilbestrol, (Z)-Isomer,Diethylstilbestrol, Disodium Salt,Distilbène,Stilbene Estrogen,Tampovagan,Estrogen, Stilbene
D004961 Estramustine A nitrogen mustard linked to estradiol, usually as phosphate; used to treat prostatic neoplasms; also has radiation protective properties. Estramustinphosphate,Emcyt,Estracyt,Estramustin Phosphate,Estramustine Phosphate Sodium,Leo-275,NSC-89199,Leo 275,Leo275,NSC 89199,NSC89199,Phosphate Sodium, Estramustine,Phosphate, Estramustin

Related Publications

H Toma, and R Nakamura, and S Onitsuka, and N Goya, and H Nakazawa
October 1994, Journal of clinical pathology,
H Toma, and R Nakamura, and S Onitsuka, and N Goya, and H Nakazawa
January 1988, European urology,
H Toma, and R Nakamura, and S Onitsuka, and N Goya, and H Nakazawa
January 1976, European urology,
H Toma, and R Nakamura, and S Onitsuka, and N Goya, and H Nakazawa
September 2006, Urology,
H Toma, and R Nakamura, and S Onitsuka, and N Goya, and H Nakazawa
May 1980, Investigative urology,
H Toma, and R Nakamura, and S Onitsuka, and N Goya, and H Nakazawa
January 2005, Scandinavian journal of urology and nephrology,
H Toma, and R Nakamura, and S Onitsuka, and N Goya, and H Nakazawa
June 2000, Virchows Archiv : an international journal of pathology,
H Toma, and R Nakamura, and S Onitsuka, and N Goya, and H Nakazawa
January 1995, Urological research,
H Toma, and R Nakamura, and S Onitsuka, and N Goya, and H Nakazawa
January 1984, The Turkish journal of pediatrics,
Copied contents to your clipboard!